Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.


Journal

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
ISSN: 1827-675X
Titre abrégé: Acta Otorhinolaryngol Ital
Pays: Italy
ID NLM: 8213019

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 15 01 2023
accepted: 19 01 2023
medline: 13 9 2023
pubmed: 12 9 2023
entrez: 12 9 2023
Statut: ppublish

Résumé

Recurrent respiratory papillomatosis (RRP) is a benign, rare disease caused by Human Papilloma Virus (HPV) that can be divided into juvenile and adult forms. The course of the disease is variable, but is usually more aggressive in the juvenile form. The standard surgical treatment is represented by CO A retrospective analysis of the clinical charts of all patients affected by laryngeal papillomatosis and treated in three different University Centres between 2002 and 2022 was performed. The following parameters were collected: sex, age at first evaluation, sites of larynx involved, HPV type, type of first surgical treatment, presence and number of recurrences, surgical treatment of recurrences, adjuvant therapies, side effects and status at last follow-up. Seventy-eight patients were available for evaluation. Of these, 88% had adult onset RRP (Ao-RRP) and 12% juvenile onset RRP (Jo-RRP). The glottis was the most frequently involved subsite; all patients were submitted to surgical resection with CO Our results confirmed the literature review. RRP is a potentially aggressive disease, especially in juvenile onset. Surgical resection is still first-line treatment, but in case of multiple recurrences the use of adjuvant therapies must be taken into consideration. La papillomatosi laringea ricorrente: strategie terapeutiche multimodali. Revisione della letteratura e analisi retrospettiva multicentrica. La papillomatosi recidivante delle vie respiratorie è una rara patologia benigna causata dal Papilloma virus umano (HPV) e può essere suddivisa in una forma giovanile ed una dell’adulto. Il decorso della malattia è variabile, di solito più aggressivo nella forma giovanile. Il trattamento chirurgico standard è rappresentato dalla resezione con laser CO È stata condotta un’analisi retrospettiva sulle cartelle cliniche dei pazienti affetti da papillomatosi laringea e trattati in tre differenti Centri Universitari tra il 2002 e il 2022. Sono stati analizzati i seguenti parametri: sesso, età alla prima visita, siti laringei coinvolti, sierotipi di HPV, tipologia del primo trattamento chirurgico, presenza e numero di recidive, trattamento chirurgico delle recidive, terapie adiuvanti, effetti collaterali e status all’ultimo follow-up. Settantotto pazienti sono stati selezionati per lo studio. Di questi, l’88% presentava papillomatosi dell’adulto (Ao-RRP) e il 12% una forma giovanile (Jo-RRP). La glottide è risultata la sottosede più coinvolta; tutti i pazienti sono stati sottoposti a chirurgia con laser CO I risultati hanno confermato quelli della revisione della letteratura. La papillomatosi respiratoria ricorrente è una malattia potenzialmente aggressiva, specie nell’insorgenza giovanile. La resezione chirurgica è ancora il trattamento di prima linea, ma in caso di multiple recidive è necessario prendere in considerazione l’uso di terapie adiuvanti.

Autres résumés

Type: Publisher (ita)
La papillomatosi laringea ricorrente: strategie terapeutiche multimodali. Revisione della letteratura e analisi retrospettiva multicentrica.

Identifiants

pubmed: 37698108
doi: 10.14639/0392-100X-suppl.1-43-2023-14
pmc: PMC10159644
doi:

Substances chimiques

Carbon Dioxide 142M471B3J

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S111-S122

Informations de copyright

Copyright © 2023 Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Rome, Italy.

Références

Eur Arch Otorhinolaryngol. 2016 May;273(5):1207-14
pubmed: 26677852
Acta Otorhinolaryngol Ital. 2022 Apr;42(2):189-193
pubmed: 35612512
Otolaryngol Clin North Am. 2012 Jun;45(3):671-94, viii-ix
pubmed: 22588043
Eur Arch Otorhinolaryngol. 2000;257(5):263-9
pubmed: 10923940
Laryngoscope Investig Otolaryngol. 2019 Jan 07;4(1):89-94
pubmed: 30828624
Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):976-82
pubmed: 12975271
Int J Pediatr Otorhinolaryngol. 2004 Apr;68(4):413-8
pubmed: 15013606
Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1239-43
pubmed: 11031411
Ann Otol Rhinol Laryngol. 2012 Sep;121(9):587-93
pubmed: 23012897
Cochrane Database Syst Rev. 2012 Dec 12;12:CD005053
pubmed: 23235619
Oncol Lett. 2014 Nov;8(5):1912-1918
pubmed: 25289079
Arch Otolaryngol Head Neck Surg. 1999 Jul;125(7):743-8
pubmed: 10406310
Ann Otol Rhinol Laryngol Suppl. 2009 Sep;201:1-13
pubmed: 19845188
Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1081-5
pubmed: 14568791
Laryngoscope Investig Otolaryngol. 2018 Jan 14;3(1):22-34
pubmed: 29492465
Int J Pediatr Otorhinolaryngol. 2022 Nov;162:111314
pubmed: 36116179
Laryngoscope. 1992 Jan;102(1):9-13
pubmed: 1309932
Ann Otol Rhinol Laryngol. 2004 Nov;113(11):859-62
pubmed: 15562893
Eur Arch Otorhinolaryngol. 2011 Sep;268(9):1305-11
pubmed: 21519834
Ann Otol Rhinol Laryngol. 2008 Jul;117(7):477-83
pubmed: 18700421
Hum Vaccin Immunother. 2016 Jun 2;12(6):1357-62
pubmed: 27217191
Ear Nose Throat J. 2021 Feb;100(1_suppl):105S-112S
pubmed: 32970490
JAMA Otolaryngol Head Neck Surg. 2013 May;139(5):496-501
pubmed: 23681032
Int J Pediatr Otorhinolaryngol. 2006 Nov;70(11):1911-7
pubmed: 16919339
Ann Otol Rhinol Laryngol. 2006 Sep;115(9):667-72
pubmed: 17044537
Acta Otorrinolaringol Esp (Engl Ed). 2022 Mar-Apr;73(2):82-88
pubmed: 35397828
Eur Arch Otorhinolaryngol. 2012 Feb;269(2):361-2
pubmed: 22020697
Eur Arch Otorhinolaryngol. 2020 Jun;277(6):1715-1723
pubmed: 32112142
Laryngoscope. 1998 Jun;108(6):935-7
pubmed: 9628513
Ann Otol Rhinol Laryngol. 2011 Oct;120(10):627-34
pubmed: 22097147
Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):711-6
pubmed: 15210551
Lasers Med Sci. 2019 Sep;34(7):1433-1440
pubmed: 30762194
J Infect Dis. 2019 Mar 15;219(7):1016-1025
pubmed: 30358875
Eur Arch Otorhinolaryngol. 2018 Jun;275(6):1557-1567
pubmed: 29675755
Eur Arch Otorhinolaryngol. 2013 May;270(5):1679-87
pubmed: 23377227
Ann Otol Rhinol Laryngol. 2004 Apr;113(4):265-76
pubmed: 15112968
Laryngoscope. 2021 Jun;131(6):E1941-E1949
pubmed: 33405268
Laryngoscope Investig Otolaryngol. 2022 Jul 16;7(4):970-981
pubmed: 36000042
Acta Otorrinolaringol Esp (Engl Ed). 2021 Mar-Apr;72(2):109-120
pubmed: 32312478
Biomed Res Int. 2014;2014:285486
pubmed: 25025043
Laryngoscope. 2021 May;131(5):1138-1146
pubmed: 32959914
Int J Environ Res Public Health. 2022 Jul 18;19(14):
pubmed: 35886569
Am J Otolaryngol. 2020 Mar - Apr;41(2):102321
pubmed: 31787356
Ann Otol Rhinol Laryngol. 2005 Apr;114(4):289-95
pubmed: 15895784
J Laryngol Otol. 2021 Nov;135(11):958-963
pubmed: 34470689
Laryngoscope. 2002 Apr;112(4):696-9
pubmed: 12150526
J Laryngol Otol. 2011 Mar;125(3):288-96
pubmed: 21054921
J Voice. 2017 Jan;31(1):104-106
pubmed: 27068425
Ann Otol Rhinol Laryngol. 2015 Nov;124(11):886-92
pubmed: 26056395

Auteurs

Giulia Bertino (G)

Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Fabio Pedretti (F)

Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Simone Mauramati (S)

Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Marta Filauro (M)

Unit of Otolaryngology Head and Neck Surgery, IRCCS Policlinico San Martino Hospital, Genoa, Italy.

Alberto Vallin (A)

Unit of Otolaryngology Head and Neck Surgery, IRCCS Policlinico San Martino Hospital, Genoa, Italy.
DISC, University of Genoa, Italy.

Francesco Mora (F)

Unit of Otolaryngology Head and Neck Surgery, IRCCS Policlinico San Martino Hospital, Genoa, Italy.
DISC, University of Genoa, Italy.

Erika Crosetti (E)

ENT Unit, Oncology Department, University of Turin, Orbassano (Turin), Italy.

Giovanni Succo (G)

ENT Department, San Giovanni Bosco Hospital, Turin, Italy.
Oncology Department, University of Turin, Turin, Italy.

Giorgio Peretti (G)

Unit of Otolaryngology Head and Neck Surgery, IRCCS Policlinico San Martino Hospital, Genoa, Italy.
DISC, University of Genoa, Italy.

Marco Benazzo (M)

Department of Otolaryngology Head and Neck Surgery, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH